NYSE:SYK - Stryker Stock Price, Forecast & News

Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."

Stryker declared a quarterly dividend on Friday, February 7th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.575 per share on Thursday, April 30th. This represents a $2.30 annualized dividend and a yield of 1.02%. The ex-dividend date of this dividend is Monday, March 30th. View Stryker's Dividend History.

Stryker Co. (NYSE:SYK) released its quarterly earnings results on Tuesday, January, 28th. The medical technology company reported $2.49 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.46 by $0.03. The medical technology company earned $4.13 billion during the quarter, compared to analyst estimates of $4.11 billion. Stryker had a net margin of 13.99% and a return on equity of 25.75%. The business's revenue was up 8.8% on a year-over-year basis. During the same period last year, the company posted $2.18 earnings per share. View Stryker's Earnings History.

Stryker is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Stryker.

Stryker issued an update on its FY20 earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of $9.00-9.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.04.

22 analysts have issued 1-year price objectives for Stryker's stock. Their forecasts range from $192.00 to $250.00. On average, they anticipate Stryker's share price to reach $229.10 in the next year. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Price Targets for Stryker.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.

Media headlines about SYK stock have been trending neutral on Wednesday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Stryker earned a media sentiment score of 0.1 on InfoTrie's scale. They also gave media coverage about the medical technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Stryker.

Stryker saw a increase in short interest in January. As of January 15th, there was short interest totalling 3,910,000 shares, an increase of 10.8% from the December 31st total of 3,530,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.1% of the shares of the stock are short sold. View Stryker's Current Options Chain.

Some companies that are related to Stryker include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stryker investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Home Depot (HD), Visa (V), AbbVie (ABBV), Boeing (BA), Medtronic (MDT), NVIDIA (NVDA), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Stryker's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Greenleaf Trust (5.74%), State Street Corp (3.66%), FMR LLC (2.91%), Capital Research Global Investors (2.54%), Bank of New York Mellon Corp (1.86%) and Franklin Resources Inc. (1.52%). Company insiders that own Stryker stock include Allan C Golston, Bijoy Sagar, David Floyd, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Institutional Ownership Trends for Stryker.

SYK stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, FMR LLC, Capital International Investors, Alliancebernstein L.P., Massachusetts Financial Services Co. MA, Janus Henderson Group PLC, Jensen Investment Management Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Stryker company stock in the last year include Allan C Golston, Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.

SYK stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Point72 Asset Management L.P., CWS Financial Advisors LLC, PGGM Investments, State Street Corp, Schroder Investment Management Group, GQG Partners LLC and UBS Group AG. View Insider Buying and Selling for Stryker.

Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYK stock can currently be purchased for approximately $225.10.

Stryker has a market capitalization of $84.32 billion and generates $14.88 billion in revenue each year. The medical technology company earns $2.08 billion in net income (profit) each year or $8.26 on an earnings per share basis. Stryker employs 40,000 workers across the globe.View Additional Information About Stryker.

The official website for Stryker is http://www.strykercorp.com/.

Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]